VRTX vs IONS Stock Comparison: AI Score, Valuation, Performance and Upside
Vertex Pharmaceuticals is generally evaluated as a highly profitable, franchise-driven biotech with a dominant cystic fibrosis business, while Ionis Pharmaceuticals is assessed as a platform company transitioning from a royalty and partnership model toward building its own independent commercial products. The comparison contrasts an established profit engine against a company still scaling its self-commercialization strategy.
Use this comparison to weigh Vertex's established franchise profitability against Ionis's platform diversification and transition toward independent commercialization.
VRTX holds the edge across 4 of 5 key metrics in this comparison. VRTX leads on both 1-year return (+22.52%) and forward P/E quality (24.63x vs -56.24x for IONS), a relatively favorable combination of momentum and valuation. VRTX leads on both revenue growth (12.50%) and operating margin (38.05%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for IONS (+43.92%) than for VRTX (+3.96%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to an established, highly profitable biotech franchise
- Value pipeline diversification beyond a single disease area
- Prefer lower binary clinical trial risk than earlier-stage biotechs
- Are comfortable with a premium valuation reflecting franchise quality
- Believe antisense technology has broad, durable therapeutic applicability
- Want exposure to a company transitioning from royalties to independent product sales
- Value a diversified pipeline spanning multiple disease categories
- Are comfortable with commercial ramp execution risk on newer launches
| Metric | VRTX | IONS |
|---|---|---|
| AI scorei | 56.3 | 34.1 |
| AI ranki | #142 | #1712 |
| Latest closei | $499.74 | $42.94 |
| 1M returni | -2.63% | -4.24% |
| 3M returni | +2.90% | -21.05% |
| 6M returni | +13.27% | -43.28% |
| 1Y returni | +22.52% | -40.68% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VRTX | IONS |
|---|---|---|
| 1Y ago | $12.23K (+22.3%) started 2025-10-16 | $5.88K (-41.2%) started 2025-10-16 |
| 5Y ago | $27.64K (+176.4%) started 2021-10-18 | $14.2K (+42.0%) started 2021-10-18 |
| 10Y ago | $62.08K (+520.8%) started 2016-10-17 | $14.87K (+48.7%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | VRTX | IONS |
|---|---|---|
| Market capi | $137.3B | $10.16B |
| Trailing P/Ei | 31.55 | N/A |
| Forward P/Ei | 24.63 | -56.24 |
| Price/Salesi | 10.42 | N/A |
| EV/Revenuei | 10.44 | 11.48 |
| Analyst targeti | $563.12 | $88.00 |
| Target upsidei | +3.96% | +43.92% |
| Metric | VRTX | IONS |
|---|---|---|
| Revenue growthi | 12.50% | -40.70% |
| Earnings growthi | 8.00% | N/A |
| EPS growthi | +8.00% | N/A |
| FCF margini | +20.88% | -39.67% |
| Operating margini | 38.05% | -38.18% |
| Profit margini | 35.00% | -64.66% |
| ROIC proxyi | 23.54% | -105.50% |
| Return on equityi | 23.54% | -105.50% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.30 | 0.40 |
| Debt/equityi | 9.77 | 497.80 |
| Current ratioi | 3.19 | 7.89 |
| Quick ratioi | 2.54 | 6.85 |
Over the past year, VRTX and IONS have moved weakly in the same direction (correlation of 0.34), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VRTX | IONS |
|---|---|---|---|
| 1Y | Growthi | +22.30% | -41.23% |
| CAGRi | +22.34% | -41.28% | |
| Volatilityi | 28.84% | 42.34% | |
| Sharpe ratioi | 0.69 | -1.14 | |
| Sortino ratioi | 1.11 | -1.35 | |
| Max drawdowni | 15.21% | 51.01% | |
| Current drawdowni | 10.43% | 50.36% | |
| Avg drawdowni | 6.09% | 16.54% | |
| Ulcer Indexi | 7.64% | 22.63% | |
| Max daily dropi | 4.56% | 23.90% | |
| Max wkly dropi | 9.32% | 36.37% | |
| 5Y | Growthi | +176.40% | +41.95% |
| CAGRi | +22.57% | +7.27% | |
| Volatilityi | 29.09% | 43.84% | |
| Sharpe ratioi | 0.70 | 0.27 | |
| Sortino ratioi | 0.97 | 0.41 | |
| Max drawdowni | 29.07% | 52.36% | |
| Current drawdowni | 10.43% | 50.36% | |
| Avg drawdowni | 7.32% | 17.21% | |
| Ulcer Indexi | 9.61% | 21.40% | |
| Max daily dropi | 20.60% | 23.90% | |
| Max wkly dropi | 20.71% | 36.37% | |
| 10Y | Growthi | +520.80% | +48.74% |
| CAGRi | +20.04% | +4.05% | |
| Volatilityi | 32.61% | 45.62% | |
| Sharpe ratioi | 0.59 | 0.22 | |
| Sortino ratioi | 0.87 | 0.31 | |
| Max drawdowni | 41.60% | 70.39% | |
| Current drawdowni | 10.43% | 50.36% | |
| Avg drawdowni | 10.89% | 36.82% | |
| Ulcer Indexi | 14.64% | 41.27% | |
| Max daily dropi | 20.70% | 23.90% | |
| Max wkly dropi | 22.29% | 36.37% |
| Category | VRTX | IONS |
|---|---|---|
| Company | Vertex Pharmaceuticals Incorporated | Ionis Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Vertex Pharmaceuticals develops and markets therapies for cystic fibrosis and is expanding into pain management, diabetes, and gene-editing treatments through its clinical pipeline. | Ionis Pharmaceuticals develops antisense oligonucleotide therapies targeting a broad range of rare and common diseases, both independently and through partnerships with larger pharmaceutical companies. |
| Investor focus | Investors watch cystic fibrosis franchise durability, commercial uptake of newer non-opioid pain and gene-editing therapies, and pipeline diversification progress. | Investors track the commercial ramp of its independently marketed therapies, partnership milestone and royalty revenue, and pipeline progress across multiple disease areas. |
- Dominant, highly profitable franchise in cystic fibrosis treatments
- Strong balance sheet funding pipeline diversification efforts
- Approved gene-editing and non-opioid pain therapies expanding beyond core franchise
- Proven, validated antisense drug discovery platform with decades of development history
- Growing base of independently commercialized products alongside partner royalties
- Diversified pipeline spanning cardiovascular, neurological, and rare diseases
- Long-term reliance on cystic fibrosis franchise for the bulk of revenue
- New therapy launches carry commercial execution and reimbursement risk
- Patent and competitive dynamics in core disease areas over time
- Newer independently marketed products still building commercial scale
- Reliance on partnership economics for a portion of pipeline value
- Competitive pressure from other RNA-targeted therapeutic modalities
Compare more than two at a time
This page is a fixed writeup on VRTX and IONS. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside VRTX and IONS, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.